Avery Therapeutics’ mission is to repair hearts and improve quality of life for patients with heart failure. To address this large unmet medical need, Avery is developing MyCardia™, an engineered cardiac tissue. Once manufactured, these tissues behave like cardiac tissue, and importantly can be cryopreserved for storage and transport. These tissues are then implanted directly onto the heart and have been shown, in pre-clinical models of heart failure, to improve both cardiac performance and quality of life. Avery is also developing therapies for cardiac arrythmias, such as atrial fibrillation. In total, these products can improve the lives of millions of patients around the world.